Leflunomide and Ibrance drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Leflunomide (leflunomide) and Ibrance (palbociclib). Common drug interactions include fatigue among females.

The phase IV clinical study analyzes what interactions people have when they take Leflunomide and Ibrance. It is created by eHealthMe based on reports of 17 people who take the same drugs from the FDA, and is updated regularly.

What is Leflunomide?

Leflunomide has active ingredients of leflunomide. It is often used in rheumatoid arthritis. eHealthMe is studying from 82,105 Leflunomide users. Check the latest studies of Leflunomide.

What is Ibrance?

Ibrance has active ingredients of palbociclib. eHealthMe is studying from 104,434 Ibrance users. Check the latest studies of Ibrance.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 18, 2026

17 people who take Leflunomide and Ibrance together, and have interactions are studied.

Leflunomide and Ibrance drug interactions.

What are the common drug interactions of Leflunomide and Ibrance, by gender? *:

female:

Fatigue (feeling of tiredness)
White blood cell count decreased
Dysgeusia (disorder of the sense of taste)
Abdominal pain upper
Full blood count decreased
Musculoskeletal chest pain (pain in chest muscle or nerve or bones)
Red blood cell count decreased
Blood potassium decreased
Tumour marker increased
Cerebrovascular accident (sudden death of some brain cells due to lack of oxygen when the blood flow to the brain is impaired by blockage or rupture)

male:

n/a

What are the common drug interactions of Leflunomide and Ibrance, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

White blood cell count decreased
Abdominal pain upper
Full blood count decreased
Musculoskeletal chest pain (pain in chest muscle or nerve or bones)
Red blood cell count decreased
Blood potassium decreased
Cerebrovascular accident (sudden death of some brain cells due to lack of oxygen when the blood flow to the brain is impaired by blockage or rupture)
Cough
Hypoaesthesia (reduced sense of touch or sensation)
Infection

60+:

Fatigue (feeling of tiredness)
Platelet count decreased
Dysgeusia (disorder of the sense of taste)
Tumour marker increased
Neutropenia (an abnormally low number of neutrophils)
White blood cell count decreased
Emotional disorder
Anxiety
Depression
International normalised ratio increased

What are the existing conditions these people have? *

Breast Cancer Metastatic: 5 people, 29.41%
Lymphoma (cancer that begins in immune system cells): 4 people, 23.53%
Breast Cancer: 3 people, 17.65%
Hypersensitivity: 2 people, 11.76%
Gastric Disorder (disease of stomach): 2 people, 11.76%
Fluid Imbalance (imbalance of fluid in body in intake and fluid lost): 2 people, 11.76%
Cardiac Disorder: 2 people, 11.76%
Blood Pressure Abnormal: 2 people, 11.76%
Arrhythmias (irregular heartbeat): 2 people, 11.76%

* Approximation only. Some reports may have incomplete information.

Do you take Leflunomide and Ibrance?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously